ArticleFrontiers in neurology2025
Efficacy of ceftazidime-avibactam for the treatment of central nervous system infection caused by carbapenem-resistant
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-ProducingInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: A retrospective analysis was conducted on patients with CRKP-positive cerebrospinal fluid (CSF) samples admitted to the CSF Neurosurgery Department of the Aviation General Hospital between August 2019 and November 2021. Data collected included patient demographics, medical history, laboratory results, etiological findings, and antibiotic treatments. Nine patients with CRKP-induced CNS infections who were treated with Ceftazidime-avibactam (CAZ-AVI) were included in the analysis. The study assessed clinical features, treatment courses, and patient outcomes. Results: Of the nine patients, 88.9% (8/9) achieved both clinical and etiological cure. One patient experienced relapse 20 days after initial CSF culture negativity, with the family opting for discontinuation of further treatment. Following infection resolution, patients exhibited varying degrees of neurological improvement, including one case of complete recovery from a comatose state (GCS 6 to GCS 15). Treatment-related adverse effects included transient liver dysfunction in one patient and diarrhea in three, which resolved with symptomatic management. CSF drainage tubes were removed in three patients following treatment, while five required shunt surgery due to hydrocephalus. No relapses were reported in treated patients during a follow-up period of 3-12 months. Conclusion: Intravenous CAZ-AVI combined with intracerebroventricular or intrathecal polymyxin B or amikacin demonstrated promising efficacy as a treatment regimen for CRKP-induced CNS infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.